.jpg "Rare Tumor Initiative Team Patient Mosaic Team, N/A photo")
N/A
MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center Rare Tumor Initiative (RTI) was established to deeply analyze the tumors from patients with rare cancers with the goal of enhancing our understanding of the tumor and the tumor microenvironment, developing patient-derived tumor cells lines and animal models, and identifying new molecular targets. The RTI generated whole exome sequencing data, RNA sequencing data, and Vectra multiplex immunofluorescence data. Through large-scale assessments of patient molecular and clinical data, the effort allows for the definition of the role and magnitude of molecular variation in relevant clinical phenotypes ranging from risk, response, and toxicity to long-term outcomes.
The University of Texas MD Anderson Patient Mosaic™ launched in September 2021, expanding the efforts of the RTI, which formally ended in 2021. Patient Mosaic is dedicated to collecting biospecimens and data, analyzing the specimens, organizing and integrating the resulting data, managing and enriching the combined data and samples from at least 10,000 patients with cancer at MD Anderson. This effort ultimately allows physicians and researchers to assess and further generate key insights toward the development of tools and strategies for prediction, rational risk reduction, prevention, treatment, toxicity management/avoidance and improvement of long-term quality of life, thus gaining more power and insight as more data are incorporated — all with the singular goal of improving patient outcomes, saving lives and, ultimately, ending cancer.
